Tags : Opioid Use Disorder

Orexo Enters into an Agreement with GAIA to Develop and

Shots: GAIA to receive royalties, milestone and financial compensation during the development phase. Orexo to get exclusive WW rights to commercialize DTx (OXD-01) and is responsible for the clinical development, regulatory approval and commercialization activities The DTx is based on GAIA’s Broca technology platform which is an AI-expert system that engaged users in personalized and […]Read More